The DOI matches its Crossref record; 47 of the 47 references it cites were found in a registry or an index.
Reporting Recommendations for Tumor Marker Prognostic Studies (REMARK)
Abstract
Despite years of research and hundreds of reports on tumor markers in oncology, the number of markers that have emerged as clinically useful is pitifully small. Often, initially reported studies of a marker show great promise, but subsequent studies on the same or related markers yield inconsistent conclusions or stand in direct contradiction to the promising results. It is imperative that we attempt to understand the reasons that multiple studies of the same marker lead to differing conclusions. A variety of methodologic problems have been cited to explain these discrepancies. Unfortunately, many tumor marker studies have not been reported in a rigorous fashion, and published articles often lack sufficient information to allow adequate assessment of the quality of the study or the generalizability of study results. The development of guidelines for the reporting of tumor marker studies was a major recommendation of the National Cancer Institute-European Organisation for Research and Treatment of Cancer (NCI-EORTC) First International Meeting on Cancer Diagnostics in 2000. As for the successful CONSORT initiative for randomized trials and for the STARD statement for diagnostic studies, we suggest guidelines to provide relevant information about the study design, preplanned hypotheses, patient and specimen characteristics, assay methods, and statistical analysis methods. In addition, the guidelines suggest helpful presentations of data and important elements to include in discussions. The goal of these guidelines is to encourage transparent and complete reporting so that the relevant information will be available to others to help them to judge the usefulness of the data and understand the context in which the conclusions apply.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“While making revisions, conscious efforts were made to harmonize our recommendations with other reporting guidelines, and where possible we chose the same or similar wording for items [37,39,41,45,46].”
From Transparent reporting of a multivariable prediction model for individual prognosis or diagnosis (TRIPOD): the TRIPOD Statement (2015) · cites this paper as [37]
In the citing paper
“These items have been identified as important in several well-known guidelines for reporting of clinical research [4],[38]–[41].”
From Reporting and Methods in Clinical Prediction Research: A Systematic Review (2012) · cites this paper as [4]
In the citing paper
“Most guidelines, such as the STROBE guidelines for the reporting of observational studies or the REMARK guidelines for tumour marker prognostic studies, specifically advise investigators to report both unadjusted results (i.e., from univariable analysis, yielding the association of each candidate predictor with the outcome) and adjusted results (i.e., from a multivariable analysis) [4],[38],[63].”
From Reporting and Methods in Clinical Prediction Research: A Systematic Review (2012) · cites this paper as [4]
In the citing paper
“However, none of these guidelines are entirely appropriate for prediction model studies.”
From Transparent Reporting of a Multivariable Prediction Model for Individual Prognosis or Diagnosis (TRIPOD): The TRIPOD Statement (2015) · cites this paper as [37]
In the citing paper
“However, the focus of the REMARK checklist is primarily on prognostic factors and not prediction models, whereas the GRIPS statement is aimed at risk prediction using genetic risk factors and the specific methodological issues around handling large numbers of genetic variants.”
From Transparent Reporting of a Multivariable Prediction Model for Individual Prognosis or Diagnosis (TRIPOD): The TRIPOD Statement (2015) · cites this paper as [37]
Citations
Cites
Meta-analysis of Observational Studies in Epidemiology<SUBTITLE>A Proposal for Reporting</SUBTITLE>
Stroup, D. F. (2000) · JAMA · doi:10.1001/jama.283.15.2008 · Cited by 20,623
Moher, D., Schulz, K. F., & Altman, D. G. (2001) · The Lancet · doi:10.1016/s0140-6736(00)04337-3 · Cited by 5,373
Self-citationMoher, D., Cook, D. J., Eastwood, S., Olkin, I., Rennie, D., & Stroup, D. F. (1999) · The Lancet · doi:10.1016/s0140-6736(99)04149-5 · Cited by 4,826
The Revised CONSORT Statement for Reporting Randomized Trials: Explanation and Elaboration
Altman, D. G., Schulz, K. F., Moher, D., Egger, M., Davidoff, F., Elbourne, D., Gøtzsche, P. C., Lang, T., & for the CONSORT Group (2001) · Annals of Internal Medicine · doi:10.7326/0003-4819-134-8-200104170-00012 · Cited by 3,835
Self-citationTowards complete and accurate reporting of studies of diagnostic accuracy: The STARD Initiative.
Bossuyt, P. M., Reitsma, J. B., Bruns, D. E., Gatsonis, C. A., Glasziou, P. P., Irwig, L. M., Lijmer, J. G., Moher, D., Rennie, D., de Vet, H. C. W., et al. (2003) · Annals of Internal Medicine · doi:10.7326/0003-4819-138-1-200301070-00010 · Cited by 3,219
Towards complete and accurate reporting of studies of diagnostic accuracy: the STARD initiative
Bossuyt, P. M., Reitsma, J. B., Bruns, D. E., Gatsonis, C. A., Glasziou, P. P., Irwig, L. M., Lijmer, J. G., Moher, D., Rennie, D., & de Vet, H. C. W. (2003) · BMJ · doi:10.1136/bmj.326.7379.41 · Cited by 3,215
Moher, D. (2001) · JAMA · doi:10.1001/jama.285.15.1987 · Cited by 2,545
Systematic Reviews in Health Care : Meta-Analysis in Context
Egger, M., Smith, G. D., & Altman, D. G. (2000) · Cited by 2,312
Self-citationDangers of Using "Optimal" Cutpoints in the Evaluation of Prognostic Factors
Altman, D. G., Lausen, B., Sauerbrei, W., & Schumacher, M. (1994) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/86.11.829 · Cited by 1,143
Self-citationThe Risk of Determining Risk with Multivariable Models
Concato, J., Feinstein, A. R., & Holford, T. R. (1993) · Annals of Internal Medicine · doi:10.7326/0003-4819-118-3-199302010-00009 · Cited by 1,129
Cited by
Sorted by citations
Items 701–800 of 1,003
Zhao, Y., Wang, L., Dai, Z., Wang, D., Hei, Z., Zhang, N., Fu, X., Wang, X., Zhang, S., Qin, L., et al. (2011) · International Journal of Cancer · doi:10.1002/ijc.25918 · Cited by 48
The Prognostic Value of p16 Hypermethylation in Cancer: A Meta-Analysis
Xing, X., Cai, W., Luo, L., Liu, L.-S., Shi, H., & Chen, M. (2013) · PLoS ONE · doi:10.1371/journal.pone.0066587 · Cited by 48
Hoshimoto, S., Takeuchi, H., Ono, S., Sim, M., Huynh, J. L., Huang, S. K., Marzese, D. M., Kitagawa, Y., & Hoon, D. S. �. (2014) · Journal of Thoracic Oncology · doi:10.1097/jto.0000000000000441 · Cited by 48
A Meta-Analysis of SMAD4 Immunohistochemistry as a Prognostic Marker in Colorectal Cancer
Voorneveld, P. W., Jacobs, R. J., Kodach, L. L., & Hardwick, J. C. H. (2015) · Translational Oncology · doi:10.1016/j.tranon.2014.11.003 · Cited by 48
Ginsburg, G. S., & Kuderer, N. M. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2012.42.6114 · Cited by 48
Weerts, M. J. A., Sieuwerts, A. M., Smid, M., Look, M. P., Foekens, J. A., Sleijfer, S., & Martens, J. W. M. (2016) · Oncotarget · doi:10.18632/oncotarget.8688 · Cited by 50
Prognostic role of vascular endothelial growth factor in cervical cancer: a meta-analysis
Zhang, J., Liu, J., Zhu, C., He, J., Chen, J., Liang, Y., Yang, F., Wu, X. Y., & Ma, X. (2017) · Oncotarget · doi:10.18632/oncotarget.15044 · Cited by 49
Noske, A., Möbus, V. J., Weber, K. E., Schmatloch, S., Weichert, W., Köhne, C., Solbach, C., Heppner, B. I., Steiger, K., Müller, V., et al. (2019) · European Journal of Cancer · doi:10.1016/j.ejca.2019.04.010 · Cited by 48
Robertson, S., Ács, B., Lippert, M. F., & Hartman, J. (2020) · Breast Cancer Research and Treatment · doi:10.1007/s10549-020-05752-w · Cited by 50
Cathomas, R. L., Rothermundt, C. A., Klingbiel, D., Bubendorf, L., Jaggi, R. B., Betticher, D. C., Brauchli, P., Cotting, D., Droege, C., Winterhalder, R., et al. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-2219 · Cited by 48
Park, Y. H., Jung, H. A., Choi, M. K., Chang, W., Choi, Y., Do, I.-G., Ahn, J. S., & Im, Y.-H. (2013) · British Journal of Cancer · doi:10.1038/bjc.2013.757 · Cited by 47
Lebdai, S., Verhoest, G., Parikh, H. M., Jacquet, S. F., Bensalah, K., Chautard, D., Rioux-Leclercq, N. C., Azzouzi, A.-R., & Bigot, P. (2014) · Urologic Oncology Seminars and Original Investigations · doi:10.1016/j.urolonc.2014.06.005 · Cited by 49
Data-Based Radiation Oncology: Design of Clinical Trials in the Toxicity Biomarkers Era
Azria, D., Lapierre, A., Gourgou, S., Ruysscher, D. D., Colinge, J., Lambin, P., Brengues, M., Ward, T. H., Bentzen, S. M., Thierens, H., et al. (2017) · Frontiers in Oncology · doi:10.3389/fonc.2017.00083 · Cited by 47
IGF1R signaling drives antiestrogen resistance through PAK2/PIX activation in luminal breast cancer
Zhang, Y.-H., Wester, L., He, J., Geiger, T., Moerkens, M., Siddappa, R., Helmijr, J., Timmermans, M. M., Look, M. P., van Deurzen, C. H. M., et al. (2018) · Oncogene · doi:10.1038/s41388-017-0027-9 · Cited by 48
Westbrook, J. A., Wood, S. L., Cairns, D. A., McMahon, K., Gahlaut, R., Thygesen, H., Shires, M., Roberts, S., Marshall, H., Oliva, M. R., et al. (2019) · The Journal of Pathology · doi:10.1002/path.5197 · Cited by 47
Ghaffari, A., Hoskin, V., Turashvili, G., Varma, S., Mewburn, J., Mullins, G., Greer, P. A., Kiefer, F., Day, A. G., Madarnas, Y., et al. (2019) · Breast Cancer Research · doi:10.1186/s13058-018-1079-7 · Cited by 49
Green, A. R., Soria, D., Stephen, J., Powe, D. G., Nolan, C. C., Kunkler, I. H., Thomas, J. S. J., Kerr, G. R., Jack, W. J. L., Cameron, D., et al. (2015) · The Journal of Pathology Clinical Research · doi:10.1002/cjp2.32 · Cited by 46
Sasako, M., Terashima, M., Ichikawa, W., Ochiai, A., Kitada, K., Kurahashi, I., Sakuramoto, S., Katai, H., Sano, T., & Imamura, H. (2014) · Gastric Cancer · doi:10.1007/s10120-014-0413-8 · Cited by 46
Pharmacogenetic biomarkers for the prediction of response to antiangiogenic treatment
Schneider, B. P., Shen, F., & Miller, K. D. (2012) · The Lancet Oncology · doi:10.1016/s1470-2045(12)70275-9 · Cited by 46
Monitoring serum HER2 levels during neoadjuvant trastuzumab treatment within the GeparQuattro trial
Witzel, I., Loibl, S., von Minckwitz, G., Mundhenke, C., Huober, J., Hanusch, C. A., Henschen, S., Hauschild, M., Lantzsch, T., Tesch, H., et al. (2010) · Breast Cancer Research and Treatment · doi:10.1007/s10549-010-1030-9 · Cited by 46
Zhao, S., Yang, H., Zhang, M., Zhang, D., Liu, Y., Liu, Y., Song, Y., Zhang, X., Li, H., Ma, W., et al. (2012) · Cell Biochemistry and Biophysics · doi:10.1007/s12013-012-9426-2 · Cited by 46
Kalikaki, A., Politaki, H., Souglakos, J., Apostolaki, S., Papadimitraki, E., Georgoulia, N., Tzardi, M. N., Mavroudis, D., Georgoulias, V., & Voutsina, A. (2014) · PLoS ONE · doi:10.1371/journal.pone.0104902 · Cited by 46
eIF3a improve cisplatin sensitivity in ovarian cancer by regulating XPC and p27Kip1 translation
Zhang, Y., Yu, J., Tian, Y., Li, Z., Zhang, C.-Y., Zhang, S.-F., Cao, L., Zhang, Y., Qian, C., Zhang, W., et al. (2015) · Oncotarget · doi:10.18632/oncotarget.4555 · Cited by 46
ERCC1 and XRCC1 as biomarkers for lung and head and neck cancer
Vaezi, Niedernhofer, L. J., & Feldman (2011) · Pharmacogenomics and Personalized Medicine · doi:10.2147/pgpm.s20317 · Cited by 45
Storr, S. J., Safuan, S., Woolston, C. M., Abdel-Fatah, T. M. A., Deen, S., Chan, S. Y. T., & Martin, S. G. (2012) · Journal of Cellular and Molecular Medicine · doi:10.1111/j.1582-4934.2012.01559.x · Cited by 46
Camptothecin targets WRN protein: mechanism and relevance in clinical breast cancer
Shamanna, R. A., Lu, H., Croteau, D. L., Arora, A., Agarwal, D., Ball, G., Aleskandarany, M. A., Ellis, I. O., Pommier, Y. G., Madhusudan, S., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.7906 · Cited by 46
Boyiadzis, M. M., & Whiteside, T. L. (2016) · Expert Review of Molecular Diagnostics · doi:10.1080/14737159.2016.1174578 · Cited by 46
Huang, S., Luo, Q., Peng, H., Li, J., Zhao, M., Wang, J., Gu, Y., Li, Y., Yuan, P., Zhao, G., et al. (2018) · Medical Science Monitor · doi:10.12659/msm.909453 · Cited by 46
Asano, Y., Kashiwagi, S., Goto, W., Takada, K., Takahashi, K., Morisaki, T., Fujita, H., Takashima, T., Tomita, S., Ohsawa, M., et al. (2018) · Journal of Translational Medicine · doi:10.1186/s12967-018-1458-y · Cited by 46
Prognostic and Clinicopathologic Associations of LAG-3 Expression in Triple-negative Breast Cancer
Stovgaard, E. S., Kümler, I., List-jensen, K., Roslind, A., Christensen, I. J., Høgdall, E. V. S., Nielsen, D., & Balslev, E. (2021) · Applied immunohistochemistry & molecular morphology · doi:10.1097/pai.0000000000000954 · Cited by 46
Zheng, W., Zhou, S., Xu, J., Liu, Y., Huang, P., Liu, Y., & Chen, X. (2016) · Advanced Science · doi:10.1002/advs.201600197 · Cited by 46
Translating metastasis-related biomarkers to the clinic—progress and pitfalls
Bidard, F., Pierga, J., Soria, J., & Thiery, J. P. (2013) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2013.4 · Cited by 45
Oba, J., Nakahara, T., Abe, T., Hagihara, A., Moroi, Y., & Furue, M. (2011) · Journal of Dermatological Science · doi:10.1016/j.jdermsci.2011.02.011 · Cited by 45
Baba, Y., Watanabe, M., Shigaki, H., Iwagami, S., Ishimoto, T., Iwatsuki, M., & Baba, H. (2012) · Surgery · doi:10.1016/j.surg.2012.08.001 · Cited by 45
Mlynash, M., Buckwalter, M. S., Okada, A., Caulfield, A. F., Venkatasubramanian, C., Eyngorn, I., Verbeek, M. M., & Wijman, C. A. C. (2013) · Neurocritical Care · doi:10.1007/s12028-013-9867-5 · Cited by 44
Neutrophil/lymphocyte ratio predicts the prognosis in esophageal squamous cell carcinoma patients
Kosumi, K., Baba, Y., Ishimoto, T., Harada, K., Nakamura, K., Ohuchi, M., Kiyozumi, Y., Izumi, D., Tokunaga, R., Taki, K., et al. (2015) · Surgery Today · doi:10.1007/s00595-015-1197-0 · Cited by 45
Urine Analysis and Protein Networking Identify Met as a Marker of Metastatic Prostate Cancer
Russo, A. L., Jedlicka, K., Wernick, M., McNally, D., Kirk, M. J., Sproull, M. T., Smith, S., Shankavaram, U. T., Kaushal, A., Figg, W. D., et al. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-0599 · Cited by 45
Bentzen, S. M. (2008) · Seminars in Radiation Oncology · doi:10.1016/j.semradonc.2007.10.003 · Cited by 44
Lei, X., Xu, J., Chang, R., Fěng, F., Zuo, C., & Yang, L. (2016) · Oncotarget · doi:10.18632/oncotarget.9733 · Cited by 45
Kandimalla, R., Gao, F., Matsuyama, T., Ishikawa, T., Uetake, H., Takahashi, N., Yamada, Y., Becerra, C. R., Kopetz, S., Wang, X., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-3236 · Cited by 45
Ohue, Y., Kurose, K., Karasaki, T., Isobe, M., Yamaoka, T., Futami, J., Irei, I., Masuda, T., Fukuda, M., Kinoshita, A., et al. (2019) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2019.08.008 · Cited by 45
Sinn, M., Sinn, B. V., Treue, D., Keilholz, U., Damm, F., Schmuck, R. B., Lohneis, P., Klauschen, F., Striefler, J. K., Bahra, M., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-3034 · Cited by 45
Harnden, P., Shelley, M. D., Naylor, B., Coles, B., & Mason, M. D. (2008) · European Urology · doi:10.1016/j.eururo.2008.06.068 · Cited by 45
Harigopal, M., Barlow, W. E., Tedeschi, G., Porter, P. L., Yeh, I., Haskell, C. M., Livingston, R. B., Hortobágyi, G. N., Sledge, G. W., Shapiro, C. L., et al. (2010) · American Journal Of Pathology · doi:10.2353/ajpath.2010.090711 · Cited by 45
Inferring Relevance from Eye Movements: Feature Extraction
Salojärvi, J., Puolamäki, K., Simola, J., Kovanen, L., Kojo, I., & Samuel Kaski, A. (2005) · Cited by 45
Integrated genomic analysis identifies subclasses and prognosis signatures of kidney cancer
Christinat, Y., & Krek, W. (2015) · Oncotarget · doi:10.18632/oncotarget.3294 · Cited by 45
A Meta-Analysis of Gemcitabine Biomarkers in Patients With Pancreaticobiliary Cancers
Wei, C. H., Gorgan, T., Elashoff, D. A., Hines, O. J., Farrell, J. J., & Donahue, T. R. (2013) · Pancreas · doi:10.1097/mpa.0b013e3182a23ae4 · Cited by 44
Strengthening the reporting of genetic risk prediction studies: the GRIPS statement
Janssens, A. C. J. W., Ioannidis, J. P. A., van Duijn, C. M., Little, J., Khoury, M. J., & the GRIPS Group (2011) · Genome Medicine · doi:10.1186/gm230 · Cited by 44
Prognostic Role of Survivin in Bladder Cancer: A Systematic Review and Meta-Analysis
Jeon, C., Kim, M., Kwak, C. H., Kim, H. H., & Ku, J. H. (2013) · PLoS ONE · doi:10.1371/journal.pone.0076719 · Cited by 44
Kefalopoulou, Z. M., Tzelepi, V., Zolota, V., Grivas, P. D., Christopoulos, C., Kalofonos, H. P., Maraziotis, T., & Sotiropoulou‐Bonikou, G. (2011) · Journal of Neuro-Oncology · doi:10.1007/s11060-011-0637-y · Cited by 44
Clinical Biomarkers in Oncology
Roock, W. D., Biesmans, B., Schutter, J. D., & Tejpar, S. (2009) · Molecular Diagnosis & Therapy · doi:10.1007/bf03256319 · Cited by 44
Shu, Q., Ge, Y., Ma, H., Gao, X., Pan, J., Liu, D., Xu, G., Ma, J., & Jia, W. (2016) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.12787 · Cited by 44
Serum amyloid A expression in the breast cancer tissue is associated with poor prognosis
Yang, M., Liu, F., Higuchi, K., Sawashita, J., Fu, X., Zhang, L., Zhang, L., Fu, L., Tong, Z., & Higuchi, K. (2016) · Oncotarget · doi:10.18632/oncotarget.8561 · Cited by 44
Harada, K., Baba, Y., Shigaki, H., Ishimoto, T., Miyake, K., Kosumi, K., Tokunaga, R., Izumi, D., Ohuchi, M., Nakamura, K., et al. (2016) · BMC Cancer · doi:10.1186/s12885-016-2422-y · Cited by 45
Li, J., Wang, P., & Xu, Y. (2017) · PLoS ONE · doi:10.1371/journal.pone.0179536 · Cited by 44
Gonçalves-Ribeiro, S., Pamplona, R. S., Vidal, A. D., Sanjuán, X., Díaz-Maroto, N. G., Soriano, A., Guardiola, J., Albert, N., Martinez-Villacampa, M. M., López, I. T., et al. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx293 · Cited by 44
Grindstad, T., Richardsen, E. H., Andersen, S., Skjefstad, K., Rakaee, M., Dønnem, T., Ness, N., Nordby, Y., Bremnes, R. M., Al‐Saad, S., et al. (2018) · Scientific Reports · doi:10.1038/s41598-018-29520-5 · Cited by 44
Tumor Spread Through Air Spaces Is a Survival Predictor in Non–Small-Cell Lung Cancer
Wang, S., Hao, J., Qian, C., & Wang, H. (2019) · Clinical Lung Cancer · doi:10.1016/j.cllc.2019.05.012 · Cited by 44
CITED2 and NCOR2 in anti-oestrogen resistance and progression of breast cancer
van Agthoven, T., Sieuwerts, A. M., Veldscholte, J., Gelder, M. E. M., Smid, M., Brinkman, A., den Dekker, A. T., Leroy, I. M., van IJcken, W. F. J., Sleijfer, S., et al. (2009) · British Journal of Cancer · doi:10.1038/sj.bjc.6605423 · Cited by 44
Cytoplasmic Ezrin and Moesin Correlate with Poor Survival in Head and Neck Squamous Cell Carcinoma
Schlecht, N. F., Brandwein‐Gensler, M. S., Smith, R. V., Kawachi, N., Broughel, D., Lin, J., Keller, C. E., Reynolds, P. A., Gunn‐Moore, F. J., Harris, T. M., et al. (2012) · Head and Neck Pathology · doi:10.1007/s12105-011-0328-1 · Cited by 44
Prognostic factors for renal cell carcinoma
Furniss, D., Harnden, P., Ali, N., Royston, P. J., Eisen, T. G., Oliver, R. T. D., & Hancock, B. W. (2008) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2007.12.008 · Cited by 43
Luminal B subtype: A key factor for the worse prognosis of young breast cancer patients in China
Tang, L.-C., Jin, X., Yang, H.-Y., He, M. Y., Chang, H. R., Shao, Z., & Di, G. (2015) · BMC Cancer · doi:10.1186/s12885-015-1207-z · Cited by 43
Koelzer, V. H., Baker, K., Kassahn, D., Baumhoer, D., & Zlobec, I. (2012) · Journal of Clinical Pathology · doi:10.1136/jclinpath-2012-200742 · Cited by 43
Pra, A. D., Lalonde, E., Sykes, J. R., Warde, F., Ishkanian, A., Meng, A. X., Maloff, C., Srigley, J. R., Joshua, A. M., Petrovics, G., et al. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-1049 · Cited by 42
Mitsuhashi, K., Yamamoto, I., Kurihara, H., Kanno, S., Ito, M., Igarashi, H., Ishigami, K., Sukawa, Y., Tachibana, M., Takahashi, H., et al. (2015) · Oncotarget · doi:10.18632/oncotarget.4294 · Cited by 43
Fisher, O. M., Lord, S. J., Falkenback, D., Clemons, N. J., Eslick, G. D., & Lord, R. V. (2016) · Gut · doi:10.1136/gutjnl-2015-310888 · Cited by 43
The role of autophagy in squamous cell carcinoma of the head and neck
Cosway, B., & Lovat, P. E. (2016) · Oral Oncology · doi:10.1016/j.oraloncology.2015.12.007 · Cited by 43
Prognostic value of 18F-FDG PET-CT-based functional parameters in patients with soft tissue sarcoma
Chen, L., Wu, X. Y., Ma, X., Guo, L., Zhu, C., & Li, Q. (2017) · Medicine · doi:10.1097/md.0000000000005913 · Cited by 43
Androgen receptor expression and breast cancer mortality in a population-based prospective cohort
Elebro, K., Bendahl, P., Jernström, H., & Borgquist, S. (2017) · Breast Cancer Research and Treatment · doi:10.1007/s10549-017-4343-0 · Cited by 43
Liang, C., Pang, J., Lee, Y. H., Ooi, E. E., Ong, C. N., Leo, Y., & Tannenbaum, S. R. (2018) · PLoS neglected tropical diseases · doi:10.1371/journal.pntd.0006217 · Cited by 43
De Novo Lipogenesis Alters the Phospholipidome of Esophageal Adenocarcinoma
Abbassi‐Ghadi, N., Antonowicz, S., McKenzie, J. S., Kumar, S., Huang, J., Jones, E. A., Strittmatter, N., Petts, G., Kudo, H., Court, S., et al. (2020) · Cancer Research · doi:10.1158/0008-5472.can-19-4035 · Cited by 43
Statistical Issues in Translational Cancer Research
George, S. L. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-4537 · Cited by 43
El‐Mokadem, I., Fitzpatrick, P., Bondad, J., Rauchhaus, P., Cunningham, J., Pratt, N., Fleming, S., & Nabi, G. (2014) · British Journal of Cancer · doi:10.1038/bjc.2014.420 · Cited by 44
Yamamoto, S., Yamamoto‐Ibusuki, M., Yamamoto, Y., Fujiwara, S., & Iwase, H. (2013) · BMC Cancer · doi:10.1186/1471-2407-13-217 · Cited by 45
Matikas, A., Johansson, H., Grybäck, P., Bjöhle, J., Ács, B., Boyacı, C., Lekberg, T., Fredholm, H., Elinder, E., Margolin, S., et al. (2022) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-22-2829 · Cited by 42
Alsubhi, N. H., Middleton, F. K., Abdel-Fatah, T. M. A., Stephens, P., Doherty, R. E., Arora, A., Moseley, P. M., Chan, S. Y. T., Aleskandarany, M. A., Green, A. R., et al. (2015) · Molecular Oncology · doi:10.1016/j.molonc.2015.09.009 · Cited by 45
Zougman, A., Hutchins, G. G. A., Cairns, D. A., Verghese, E. T., Perry, S., Jayne, D. G., Selby, P. J., & Banks, R. E. (2012) · European Journal of Cancer · doi:10.1016/j.ejca.2012.07.031 · Cited by 43
Analytical and clinical evaluation of biomarkers assays: When are biomarkers ready for prime time?
Pennello, G. A. (2013) · Clinical Trials · doi:10.1177/1740774513497541 · Cited by 40
Hunter, B., Eustace, A. J., Irlam, J. J., Valentine, H. R., Denley, H., Oguejiofor, K., Swindell, R., Hoskin, P., Choudhury, A., & West, C. (2014) · British Journal of Cancer · doi:10.1038/bjc.2014.315 · Cited by 42
Prognostic Influence of Pre-Operative C-Reactive Protein in Node-Negative Breast Cancer Patients
Sicking, I., Edlund, K., Wesbuer, E., Weyer, V., Battista, M. J., Lebrecht, A., Solbach, C., Grinberg, M., Lotz, J., Hoffmann, G. M., et al. (2014) · PLoS ONE · doi:10.1371/journal.pone.0111306 · Cited by 42
Yamada, Y., Boku, N., Nishina, T., Yamaguchi, K., Denda, T., Tsuji, A., Hamamoto, Y., Konishi, K., Tsuji, Y., Amagai, K., et al. (2013) · Annals of Oncology · doi:10.1093/annonc/mdt238 · Cited by 42
Balmativola, D., Marchiò, C., Maule, M. M., Chiusa, L., Annaratone, L., Maletta, F., Montemurro, F., Kulka, J., Figueiredo, P., Varga, Z., et al. (2014) · Breast Cancer Research and Treatment · doi:10.1007/s10549-014-3192-3 · Cited by 42
Thariat, J., Étienne-Grimaldi, M.-C., Grall, D., Bensadoun, R., Cayre, A., Penault-Llorca, F. M., Veracini, L., Francoual, M., Formento, J., Dassonville, O., et al. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-2339 · Cited by 42
Downregulation of Serine Protease HTRA1 Is Associated with Poor Survival in Breast Cancer
Lehner, A. V., Magdolen, V., Schuster, T., Kotzsch, M., Kiechle, M. B., Meindl, A., Sweep, F. C. G. J., Span, P. N., & Groß, E. (2013) · PLoS ONE · doi:10.1371/journal.pone.0060359 · Cited by 42
Guidelines for development of diagnostic markers in bladder cancer
Goebell, P. J., Groshen, S. L., & Schmitz‐Dräger, B. J. (2008) · World Journal of Urology · doi:10.1007/s00345-008-0240-9 · Cited by 42
Kimbung, S., Kovács, A., Danielsson, A., Bendahl, P., Lövgren, K., Stolt, M. F., Tobin, N. P., Lindström, L. S., Bergh, J. C. S., Einbeigi, Z., et al. (2015) · Oncotarget · doi:10.18632/oncotarget.5089 · Cited by 42
Hall, C. S., Karhade, M., Bauldry, J. B. B., Valad, L. M., Kuerer, H. M., DeSnyder, S. M., & Lucci, A. (2016) · Journal of the American College of Surgeons · doi:10.1016/j.jamcollsurg.2016.02.021 · Cited by 42
Feng, Y., Yang, S., Zhang, B., & Wei, B. (2016) · OncoTargets and Therapy · doi:10.2147/ott.s102733 · Cited by 42
Nolte, S., Zlobec, I., Lugli, A., Hohenberger, W., Croner, R. S., Merkel, S., Hartmann, A., Geppert, C. I., & Rau, T. T. (2016) · The Journal of Pathology Clinical Research · doi:10.1002/cjp2.62 · Cited by 42
Johnson, T. M., Register, K. A., Schmidt, C., O’Dell, J. R., Mikuls, T. R., Michaud, K. D., & England, B. R. (2018) · Arthritis Care & Research · doi:10.1002/acr.23785 · Cited by 42
Raab, M., Sanhaji, M., Zhou, S., Rödel, F., El‐Balat, A., Becker, S., & Strebhardt, K. (2019) · Neoplasia · doi:10.1016/j.neo.2019.01.007 · Cited by 42
Zhai, T., Langendijk, J. A., van Dijk, L. V., Halmos, G. B., Witjes, M. J. H., Oosting, S. F., Noordzij, W., Sijtsema, N. M., & Steenbakkers, R. J. H. M. (2019) · Oral Oncology · doi:10.1016/j.oraloncology.2019.06.020 · Cited by 43
Pasculli, B., Barbano, R., Rendina, M., Fontana, A., Copetti, M., Mazza, T., Valori, V. M., Morritti, M. G., Maiello, E., Graziano, P., et al. (2019) · Scientific Reports · doi:10.1038/s41598-019-51581-3 · Cited by 42
Bueno, R., Richards, W. G., Harpole, D. H., Ballman, K. V., Tsao, M., Chen, Z., Wang, X., Chen, G., Chirieac, L. R., Chui, M. H., et al. (2020) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2020.07.005 · Cited by 42
Vidal, M., Chan, D. W., Gerstein, M., Mann, M., Omenn, G. S., Tagle, D., Sechi, S., & Participants, W. (2012) · Clinical Proteomics · doi:10.1186/1559-0275-9-6 · Cited by 41
Bergsland, C. H., Jeanmougin, M., Moosavi, S. H., Svindland, A., Bruun, J., Nesbakken, A., Sveen, A., & Lothe, R. A. (2022) · Modern Pathology · doi:10.1038/s41379-022-01086-8 · Cited by 43
Inhibition of STAT3/cyclinD1 pathway promotes chemotherapeutic sensitivity of colorectal caner
Qin, A., Yu, Q., Gao, Y., Tan, J., Huang, H., Qiao, Z., & Qian, W. (2015) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2015.01.048 · Cited by 43
Feng, X., Li, H., Dean, M. L., Wilson, H., Kornaga, E. N., Enwere, E. K., Tang, P. A., Paterson, A. H. G., Lees‐Miller, S. P., Magliocco, A. M., et al. (2015) · Breast Cancer Research · doi:10.1186/s13058-015-0575-2 · Cited by 41
Galván, J. A., Astudillo, A., Vallina, A., Fonseca, P. J., Izquierdo, L. G., García‐Carbonero, R., & González, M. V. (2013) · American Journal of Clinical Pathology · doi:10.1309/ajcpiv40istbxrax · Cited by 41
PI 3K/ AKT pathway regulates E‐cadherin and Desmoglein 2 in aggressive prostate cancer
Barber, A. G., Castillo-Martín, M., Bonal, D. M., Jia, A. J., Rybicki, B. A., Christiano, A. M., & Cordon‐Cardo, C. (2015) · Cancer Medicine · doi:10.1002/cam4.463 · Cited by 42
Metadata
- Authors
- McShane, L. M., Altman, D. G., Sauerbrei, W., Taube, S. E., Gion, M., & Clark, G. M.
- Affiliations
- National Institutes of Health (US)
- Corresponding author
- McShane, Lisa M.
- Venue
- JNCI: Journal of the National Cancer Institute
- Publisher
- Oxford University Press (OUP)
- Published
- 2005-08-17
- Volume
- 97
- Issue
- 16
- Pages
- 1180-1184
- ISSN
- 0027-8874 (ISSN-L)
- 1460-2105
- OpenAlex
- W2096910745
- Cited by
- 2,162
- References
- 46
- Citations by year
- 2026: 112 · 2025: 38 · 2024: 44 · 2023: 42 · 2022: 39 · 2021: 93 · 2020: 100 · 2019: 126 · 2018: 116 · 2017: 127 · 2016: 163 · 2015: 192 · 2014: 167 · 2013: 150 · 2012: 173
- FWCI
- 56.89
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- JNCI Journal of the National Cancer Institute (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Yale University
- Yale Cancer Center
- Cancer Research UK
- Translational Cancer Research Network
- National Cancer Institute (MD 20892, 20892)
- Topics
- Social Sciences › Decision Sciences › Statistics, Probability and Uncertainty › Meta-analysis and systematic reviews
- Physical Sciences › Mathematics › Statistics and Probability › Statistical Methods in Epidemiology
- Health Sciences › Medicine › Oncology › Cancer Diagnosis and Treatment
- Keywords
- tumor markers, prognostic factors, reporting guidelines, remarks, reporting quality, methodological discrepancies, research design, assay method, statistical analysis methods, cancer diagnosis, research transparency
- MeSH terms
- Humans, Neoplasms, Research Design, Biomarkers, Tumor, Information Dissemination, Biomedical Research
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
